Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)

Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV for Diabetic Tractional Retinal Detachment (IBETRA Study)

The purpose of this study is to compare the amount of intraoperative intraocular bleeding during 23-gauge pars plana vitrectomy (PPV) for diabetic traction retinal detachment (TRD) with and without preoperative intravitreal bevacizumab treatment.

Inclusion Criteria:

• Macular traction retinal detachment lasting three months or less secondary to diabetic retinopathy.

Exclusion Criteria:

• Massive vitreous hemorrhage preventing from detailed posterior pole examination;
• Previous intra-ocular surgery other than cataract surgery
• Hemodialysis, known bleeding disorders or use of anticoagulants drugs other than aspirin
• Prothrombin time, partial thromboplastin time or platelet count without normal limits
• History of previous thromboembolic events